Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!

HOWARU® Protect Earlylife

HOWARU Products, athletic woman climb satires to excise

HOWARU® Protect Earlylife

HOWARU® Protect Earlylife

According to research conducted by Wickens, published in several journals, HOWARU® Protect Earlylife (L. rhamnosus HN001™) addressed the development of infant microflora and immune system functions and reduced the incidence of eczema. 

A double-blind, randomized placebo controlled clinical study, conducted by Wickens, was designed to test the efficacy of L. rhamnosus HN001™ on the prevalence of eczema and allergic sensitization. In total, 316 mothers and their infants were divided into placebo (n=159) and EarlyLife (n=157) groups. Pregnant mothers were supplemented daily(6X109 CFU/d) from 5 weeks pre-term to 6 months post-term if they were breastfeeding. Infants were supplemented daily from birth until 2 years of age. The probiotic was administered in capsules to mothers and as powder, diluted to water, breast milk or formula, or sprinkled on top of the food to infants. At the age points of 2, 4 and 6 years the prevalence of eczema and allergic sensitization were determined by using clinical diagnosis and skin prick tests respectively.

At the age of two, the results demonstrated a significant reduction in the cumulative prevalence of eczema in the group supplemented with L. rhamnosus HN001™. By using clinical diagnosis criteria, the prevalence of eczema decreased by 49% (p=0.01) at 2 years of age and importantly the effect of L. rhamnosus HN001™ on decreasing the prevalence of eczema persisted until six years of age, when the cumulative prevalence was found to be 44% lower (p=0.01). In the six year follow-up study it was found that supplementation with L. rhamnosus HN001™ decreased the cumulative prevalence of positive skin-prick tests by 31% (p=0.04). Furthermore, at 4 years of age the relative risk of rhinoconjunctivits (rhinitis and red eyes) was found to be 62 % lower in the probiotic group (p=0.01).

Howaru Bar chart of Protect earlylife on Cumulative prevalence of eczema. The children in lactobacillus rhamnosus HN001 GROUP (blue bars) had a significantly lower cumulative prevalence of eczema at 2 4 and 6 years of age compared with children in placebo group(black bar)
ar chart of HOWARU protect earlylife , the chart content is Cumulative prevalence of allergic sensitization.By using skin prick tests children in lactobacillus rhamnosus HN001 group(blue bar) had a significantly lower cumulative prevalence (Hazard Ratio0.69; p=0.004) of allergic sensitization compared with children in placebo group(black bar).